Advocacy intelligence hub — real-time data for patient organizations
M.D. Anderson Cancer Center — PHASE2
Guangzhou Lupeng Pharmaceutical Company LTD. — PHASE3
Fondazione Italiana Linfomi - ETS — PHASE2
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
Tianjin Medical University Cancer Institute and Hospital — PHASE2
Ruijin Hospital — PHASE2
Stefano Zaffagnini
AstraZeneca — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance3
Jaypirca
(pirtobrutinib)Orphan drugLoxo Oncology, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of action Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (B...
CALQUENCE
(acalabrutinib)Orphan drugAcerta Pharma, LLC (a member of the AstraZeneca Group)
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Acalabrutinib is a small-molecule inhibitor of Bruton tyrosine kinase (BTK). Acalabrutinib and its active metabolite, ACP-586...
TECARTUS�
(brexucabtagene autoleucel)Orphan drugKite Pharma, Inc.
12.1 Mechanism of Action TECARTUS, a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and nor...
Velcade
(bortezomib)Orphan drugstandardTakeda Pharmaceuticals U.S.A., Inc.
Proteasome Inhibitor [EPC]
12.1 Mechanism of Action Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S prot...
BRUKINSA
(zanubrutinib)Orphan drugacceleratedBeOne Medicines USA, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib forms a covalent bond with a cyste...
PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.
Protein arginine methyltransferase 5 (PRMT5) is overexpressed in B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). While PRMT5 is known to regulate mult...
Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphoma.
Mantle-cell lymphoma (MCL) represents a rare B-cell malignancy with a challenging treatment situation in the case of relapsed or refractory (r/r) disease. Brexu-cel as first approved chimeric antigen ...
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
The Bridging the Gaps (BTG) in Leukemia, Lymphoma and Multiple Myeloma Consensus Conference 2025 brought together a multidisciplinary group of oncology experts to address the complexities of lymphoma ...
Understanding Hodgkin and B-Cell Non-Hodgkin Lymphoma Progression in Patients Awaiting Autologous Transplant in a Resource-Constrained Setting.
Wait times for autologous hematopoietic cell transplantation (auto-HCT) are often prolonged in resource-constrained countries due to logistical and social limitations. In chemosensitive lymphomas, suc...
Gastrointestinal mantle cell lymphoma.
Gastrointestinal mantle cell lymphoma.
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.
Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL) based on t...
Carlo Visco, MD
AOU Integrata di Verona - U.O. Ematologia -Verona -Italy
Prof. Dr. Michael Schmitt
University Hospital Heidelberg, Department V
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Kristie Blum, MD, M.D
Ohio State University
📍 ATLANTA, GA
Prof. Dr. Andreas Kulozik
University Hospital Heidelberg, University Medical Center for Children and Adolescents
Jason J Luke
Alliance for Clinical Trials in Oncology
📍 Philadelphia, Pennsylvania